Congestive Heart Failure Treatment Global Market Top Key Players – Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S) and Forecast to 2023

Global Congestive Heart Failure Treatment Market

Description

WiseGuyReports.Com adds” Congestive Heart Failure Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012 to 2016 and Forecast 2017 to 2023 “Research To Its Database.

Congestive Heart Failure Treatment market: Congestive heart failure is a chronic and progressive condition that affects the pumping capacity of heart muscles and also referred as “heart failure”. Congestive heart failure can refer to the stage in which fluid builds up around the heart and causes it to pump inefficiently. Ventricles pump blood to your body’s organs and tissues, and the atria receive blood from your body as it circulates back from the rest of your body. Congestive heart failure develops when ventricles unable to pump sufficient volume of blood to the body. Eventually, blood and other fluids can back up inside your lungs, liver, abdomen, and lower body. There are two types of congestive heart failure, they are systolic heart failure and diastolic heart failure. 

Global Congestive Heart Failure Treatment Market 

Increase in prevalence of cardiovascular diseases across regions is one the major factors expected to drive the revenue growth of congestive heart failure treatment globally. Lifestyle related factors are expected to add to growing disease incidence of CVDs. In addition growing number of obese patients are expected to bolster the congestive heart failure treatment market. ast track approvals of drugs in developed countries will propel sales revenues for the companies. Huge treatment demand for congestive heart failure is expected to boost the treatment market developing. However, the availability of the generic drugs and lack of end stage pipeline drugs and therapies for congestive heart failure treatment is about to hinder the market. 

Congestive Heart Failure Treatment market is segmented on the basis of the drug class, route of administration, and distribution channel 

Based on drug class, congestive heart failure treatment market is segmented as 
Beta Blockers 
ACE Inhibitors 
Angiotensin Receptor Blockers 
Diuretics 
Inotropic Agents 
Aldosterone Antagonist 
Calcium Channel Blockers 
Others 

 

Get sample Report @  https://www.wiseguyreports.com/sample-request/2868233-congestive-heart-failure-treatment-market-global-market-estimation-dynamics-regional

 

Based on route of administration, congestive heart failure treatment market is segmented as 
Oral 
Intravenous 

Based on distribution channel, congestive heart failure treatment market is segmented as 
Hospital Pharmacies 
Retail Pharmacies 
Online Pharmacies 

Congestive heart failure treatment market is expected to show significant growth in demand over the forecast period owing to rising incidences of cardiovascular diseases. Congestive heart failure is one of the most common medical conditions that is responsible for the death of people globally. According to WHO, around 6.5 million of people are diagnosed with congestive heart failure every year and around 2% of global population are hospitalized due to congestive heart failure. In July, 2015, Novartis launched novel combination drug Entresto (LCZ-696) a novel branded CHF drug. The prescription of mineralocorticoid receptor antagonists (MRAs), such as spironolactone, due to their efficiency in heart failure treatment is expected to increase the Congestive heart failure (CHF) treatment markets during the forecast period. Many generic manufacturers foray into the congestive heart failure treatment market due to patent expirations of CHF innovators drugs. The presence generics expected to hinder the market revenue and may hamper the uptake of new and expected novel drugs. 

Geographically congestive heart failure treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America and European markets are significantly having high growth potential for congestive heart failure treatment due to the increase in incidences of heart failures in these regions. According to American Heart Association, Heart Disease and Stroke Statistics 2017, congestive heart failure occupies 8.5% of heart diseases in US. merging markets like Asia Pacific and Latin America are set to witness significant growth in this industry due to change in demographics, healthcare reforms, healthcare expenditure, and an increase in treatment for congestive heart failure conditions. 

Some of the players in the global congestive heart failure (CHF) treatment market are AstraZeneca plc. (UK), Bristol-Myers Squibb Co. (U.S), GlaxoSmithKline plc (GSK) (UK), Merck & Co. Inc. (U.S), Mylan Inc. (U.S), Novartis AG (Switzerland), Pfizer Inc. (U.S), Sanofi (France), and Valeant Pharmaceuticals International Inc. (Canada) 
In July 2015, U.S. Food and Drug Administration (FDA) approved Novartis, Entresto (sacubitril/valsartan) tablets, previously known as LCZ696, to treat heart failure patients with reduced ejection fraction 

Enquiry About Report @ https://www.wiseguyreports.com/enquiry/2868233-congestive-heart-failure-treatment-market-global-market-estimation-dynamics-regional

 

Table of Contents -Major Key Points

Executive Summary 
Global Congestive Heart Failure Treatment Market Introduction
    2.1. Global Congestive Heart Failure Treatment Market – Taxonomy 
    2.2. Global Congestive Heart Failure Treatment Market –Definitions 
      2.2.1. Drug Class 
      2.2.2. Route of Administration 
Global Congestive Heart Failure Treatment Market Dynamics 
3.1. Drivers 
    3.2. Restraints 
    3.3. Opportunities/Unmet Needs of the Market 
    3.4. Trends 
    3.5. Global Congestive Heart Failure Treatment Market Dynamic Factors - Impact Analysis 
Global Congestive Heart Failure Treatment Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 
4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
    4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) 
    4.3. Market Opportunity Analysis 
Global Congestive Heart Failure Treatment Market, By Drug Class, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
5.1. Beta Blockers 
      5.1.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
      5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
      5.1.3. Market Opportunity Analysis 
    5.2. ACE Inhibitors 
      5.2.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
      5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
      5.2.3. Market Opportunity Analysis 
    5.3. Angiotensin Receptor Blockers 
      5.3.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
      5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
      5.3.3. Market Opportunity Analysis 
    5.4. Diuretics 
      5.4.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
      5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
      5.4.3. Market Opportunity Analysis 
    5.5. Inotropic Agents 
      5.5.1. Market Analysis, 2012 - 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn) 
      5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
      5.5.3. Market Opportunity Analysis 
………..CONTINUED

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, Industry research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)             

This release was published on openPR.